Stem cell expression profile in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.

G. Akyol, G. Yılmaz
{"title":"Stem cell expression profile in hepatocellular carcinoma, small cell dysplasia, and cirrhosis.","authors":"G. Akyol, G. Yılmaz","doi":"10.14800/SCTI.232","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with various etiologies and its incidence still continues to increase. Tumors with progenitor/stem cell (P/SC) immunophenotype are currently the main focus of interest. Human hepatic P/SCs are located in ductal plates in fetal and neonatal livers and they remain relatively constant throughout life. Enhanced self-renewal level of normal hepatic P/SCs serves as an early event in hepatocarcinogenesis. Approximately 40% of HCCs arise from P/SCs and these cells have a critical role in development and progression of HCC. Thus, CD133 expression was found to be upregulated during early liver restoration. In spite of the increasing evidence of the impact of cancer stem cells (CSCs) in hepatocarcinogenesis, the role of CSCs in the sequence of cirrhosis (Crh)-dysplastic nodules (DN)-HCC is still not clear. In our recent research, we investigated the expression rate and staining patterns of CD133 and CD90 in Crh, small cell dysplasia, and HCC. We also evaluated the relationship between the expression rates of CSC markers and the etiology of liver diseases. Among the P/SC markers, we like to attract more attention to CD133 and CD90. Both CD133 and CD90 expressions were higher in poorly differentiated HCC cases than well differentiated ones. According to the etiology, we found that the highest staining rate for CD133 in HCC cases developed in a cirrhotic background with chronic hepatitis B and D co-infection. The highest rate for CD90 was determined in HCC cases with chronic hepatitis C. Since Crh is the end-stage of chronic injury with continuing regeneration, detection of accompanying P/SC activation by CSC markers in suspicious nodules may suggest the initiation of early phases of hepatocarcinogenesis. Some other immunophenotypical features such as Glypican 3, heat shock protein-70, and glutamine synthetase stainings are also being used to diagnose precursor lesions. Facing the emerging concept of personalized treatment strategy, it is obvious that the studies in hepatocarcinogenesis related to the theory of CSCs will provide new ideas on genesis, development, and metastasis of HCC and will bring new insights for the diagnosis and treatment of these tumors.","PeriodicalId":90974,"journal":{"name":"Stem cell and translational investigation","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stem cell and translational investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/SCTI.232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with various etiologies and its incidence still continues to increase. Tumors with progenitor/stem cell (P/SC) immunophenotype are currently the main focus of interest. Human hepatic P/SCs are located in ductal plates in fetal and neonatal livers and they remain relatively constant throughout life. Enhanced self-renewal level of normal hepatic P/SCs serves as an early event in hepatocarcinogenesis. Approximately 40% of HCCs arise from P/SCs and these cells have a critical role in development and progression of HCC. Thus, CD133 expression was found to be upregulated during early liver restoration. In spite of the increasing evidence of the impact of cancer stem cells (CSCs) in hepatocarcinogenesis, the role of CSCs in the sequence of cirrhosis (Crh)-dysplastic nodules (DN)-HCC is still not clear. In our recent research, we investigated the expression rate and staining patterns of CD133 and CD90 in Crh, small cell dysplasia, and HCC. We also evaluated the relationship between the expression rates of CSC markers and the etiology of liver diseases. Among the P/SC markers, we like to attract more attention to CD133 and CD90. Both CD133 and CD90 expressions were higher in poorly differentiated HCC cases than well differentiated ones. According to the etiology, we found that the highest staining rate for CD133 in HCC cases developed in a cirrhotic background with chronic hepatitis B and D co-infection. The highest rate for CD90 was determined in HCC cases with chronic hepatitis C. Since Crh is the end-stage of chronic injury with continuing regeneration, detection of accompanying P/SC activation by CSC markers in suspicious nodules may suggest the initiation of early phases of hepatocarcinogenesis. Some other immunophenotypical features such as Glypican 3, heat shock protein-70, and glutamine synthetase stainings are also being used to diagnose precursor lesions. Facing the emerging concept of personalized treatment strategy, it is obvious that the studies in hepatocarcinogenesis related to the theory of CSCs will provide new ideas on genesis, development, and metastasis of HCC and will bring new insights for the diagnosis and treatment of these tumors.
干细胞在肝细胞癌、小细胞发育不良和肝硬化中的表达谱。
肝细胞癌(HCC)是世界范围内病因多样的最常见的癌症之一,其发病率仍在不断增加。具有祖细胞/干细胞(P/SC)免疫表型的肿瘤是目前关注的主要焦点。人肝脏P/SCs位于胎儿和新生儿肝脏的导管板中,并在一生中保持相对恒定。正常肝脏P/SCs自我更新水平的增强是肝癌发生的早期事件。大约40%的HCC起源于P/SCs,这些细胞在HCC的发生和发展中起着关键作用。因此,CD133的表达在早期肝脏恢复过程中被发现上调。尽管越来越多的证据表明癌症干细胞(CSCs)在肝癌发生中的作用,但CSCs在肝硬化(Crh)-发育不良结节(DN)-HCC序列中的作用仍不清楚。在我们最近的研究中,我们研究了CD133和CD90在Crh、小细胞发育不良和HCC中的表达率和染色模式。我们还评估了CSC标志物的表达率与肝脏疾病病因之间的关系。在P/SC标记物中,我们更倾向于关注CD133和CD90。CD133和CD90在低分化HCC中的表达均高于高分化HCC。根据病因学,我们发现HCC病例中CD133染色率最高的是合并慢性乙型肝炎和丁型肝炎的肝硬化背景。CD90在HCC合并慢性丙型肝炎患者中表达率最高。由于Crh是慢性损伤的终末期,并伴有持续的再生,因此在可疑结节中检测到CSC标志物伴随的P/SC激活可能提示肝癌发生的早期阶段。一些其他免疫表型特征,如Glypican 3、热休克蛋白70和谷氨酰胺合成酶染色也被用于诊断前驱病变。面对个性化治疗策略的新概念,显然,与csc理论相关的肝癌发生研究将为HCC的发生、发展和转移提供新的思路,并为HCC的诊断和治疗带来新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信